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A third group of dogs (Group 3, n = 9) required both 
The object of thii study was to test the hypothesis that 
administration of both serotonin S, and thromboxane A,- 
prostaglanti Hz (PGH,) receptor antagonists provides sig 
n&ant protection against epinephrine-induced cyclic coro- 
nary artery flow variations in open chest, anesthetized dogs 
with severe proximal coronary artery stenosis and endothe- 
lial injury. Three groups of dogs were studied. In Group 1 (n 
= 7) and Group 2 (n = 6), cyclic coronary flow variations 
were initiated after placement of a concentric constrictor 
around the left anterior descending coronary artery and 
were abolished by administration of either a thromboxane 
A,-prostaghuulm H, receptor antagonist, SQ29,548 (SQ) 
(Group l), or a serotonin Sz receptor antagonist, LY53,857 
(LY) (Group 2). Cyclic flow variations were restored with an 
epinephrine infusion and the second antagonist (LY for 
Group 1; SQ for Group 2) was administered to abolish 
epinephrine-induced cyclic flow variations. The rate of epi- 
nephrine infusion was increased until cyclic coronary flow 
variations returned (n = 8) or significant hemodynamic 
changes occurred. Plasma epinephrine concentrations were 
determined during a control period of cyclic coronary flow 
variations, after epinephrine restored cyclic flow variations 
in the presence of either SQ or LY, and again after epineph- 
rine restored cyclic flow variations in the presence of both SQ 
and LY. 
Platelet attachment, activation and aggregation in segments 
of coronary artery that are severely narrowed and have 
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SQ and LY to eliminate the initial cyclic coronary Bow 
variations and infused epinephrine restored cyclic flow 
variations (n = 8). Plasma epinephrine concentrations were 
determined during a control period and after cyclic coro- 
nary flow variation restoration with epinephrine. Yohim- 
hine, an alpha,-receptor antagonist, eliminated epineph- 
&e-induced cyclic coronary flow variations in the presence 
of both SQ and LY in most dogs. 
Plasma epinephrine at control was 0.03 f 0.01 ng/ml 
plasma (n = 22). Plasma epinephrine concentrations of 3.11 
f 0.63 ng/ml (n = 13) were required to restore cyclic 
coronary flow variations in the presence of either SQ or LY. 
Restoration of cyclic Row variations in the presence of both 
SQ and LY required a plasma epinephrine concentration of 
13.9 f 4.8 ng/ml (n = 18). Cyclic flow variations could not 
be restored in the presence of both SQ and LY in four dogs; 
plasma epinephrine in these dogs was 64.8 f 18.3 nglml. 
(J Am CoU Cardiol1989;13:755-63) 
Thus, combined serotonin and thromboxane receptor 
antagonists provide substantial protection against epineph- 
rine-restored cyclic coronary flow variations in this exper- 
imental model. In fact, the plasma epinephrine concentra- 
tions required to restore cyclic flow variations in the 
presence of both receptor antagonists were considerably 
higher than those normally encountered in patients during 
maximal exercise or with myocardial infarction. 
- 
established endothelial injury and atherosclerotic plaques 
are thought to be critically important in the pathogenesis of 
unstable angina (1). As platelets adhere to the damaged 
vascular wall and become activated, platelet-derived medi- 
ators may be released and activate other platelets or increase 
vascular smooth muscle tone, or both, leading ultimately to 
severe narrowing or total obstruction of the artery (2,3). 
Plasma hormones, such as epinephrine, are known to syn- 
ergistically enhance the effectiveness of other mediators of 
platelet aggregation in vitro and in vivo, and may play an 
important role in the process of dynamic obstruction of the 
narrowed, damaged coronary arteries (4-12). 
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When canine coronary arteries are endothelially injured 
and constricted to a degree sufficient to reduce mean blood 
flow at rest, coronary blood flow decreases gradually over 
several minutes but is interrupted by abrupt restorations of 
flow. This flow pattern is, at least in part, due to platelet 
aggregation, further narrowing of the arterial lumen and 
subsequent aggregate dislodgement (3,13). These repetitive 
blood flow reductions have been called cyclic coronary 
artery flow variations, and we have reported (14) that 
combined serotonin and thromboxane A, receptor block- 
ade usually eliminate cyclic flow variations, indicating 
that serotonin and thromboxane are both important in me- 
diating platelet interaction with the vascular wall and the 
occurrence of cyclic flow variations in this experimental 
model. 
The goals of the present study were 1) to determine if 
cyclic coronary artery flow variations recur with epinephrine 
administration after serotonin, thromboxane A2 or combined 
serotonin and thromboxane A, receptor blockade, and 2) to 
determine the concentration of circulating plasma epineph- 
rine required to restore cyclic flow variations after individual 
or combined serotonin and thromboxane A, receptor block- 
ade and to assess the relative protection afforded by the 
combined receptor antagonists in preventing epinephrine 
from restoring cyclic flow variations. These studies tested 
the hypothesis that combined serotonin and thromboxane A, 
receptor antagonists provide substantial protection against 
epinephrine-restored cyclic flow variations in this experi- 
mental model. 
Methods 
Surgical preparation. Mongrel dogs 17 to 34 kg of either 
gender were anesthetized with sodium pentobarbital(30 mg/ 
kg intravenously) and ventilated with room air. Catheters 
were placed in a common carotid artery and both jugular 
veins for systemic arterial pressure measurements or admin- 
istration of intravenous fluids or drugs, respectively. A 
thoracotomy was performed in the fifth left intercostal space 
and the heart was suspended in a pericardial cradle. A 
segment of the left anterior descending coronary artery was 
gently dissected free from surrounding tissue and a pulsed 
Doppler flow probe (15) was placed around the artery 
proximal to the area to be constricted, as previously de- 
scribed (3,16). Arterial blood gases were maintained within 
normal physiologic limits during each experiment. 
Experimental protocols. After surgical preparation, sys- 
tolic and diastolic arterial blood pressure, heart rate and 
coronary artery flow velocity were monitored continuously 
for a 30 min period (Hewlett Packard, model 7758 recorder). 
A plastic constrictor was placed distal to the Doppler flow 
probe on the left anterior descending coronary artery to 
narrow the diameter of the artery until peak (diastolic) flow 
velocity was reduced by approximately 50%, and after a 10 s 
A. GROUP I bi’) 
SO infusion 
I 
EPI infusion 
l_Y infusion I 
C. GROUP IU (n=9) 
SO infusion 1 
1 l_Y intvsion I 
Epinephrine infusion I 
Figure 1. Study protocols. Encircled B’s indicate blood collection 
times for epinephrine determinations; CFV = cyclic coronary flow 
variations; EPI = epinephrine; LY = LY53,857, a serotonin S, 
receptor antagonist; SQ = SQ29,548, a thromboxane H,/prostaglan- 
din H, receptor antagonist. 
total artery occlusion, reactive hyperemia was greatly atten- 
uated. Under these conditions, cyclic coronary flow varia- 
tions normally began within 15 min of constrictor placement. 
There were three protocols used in this study: 
Group 1 dogs. Regularly recurring cyclic coronary artery 
flow variations were observed for 30 min in seven dogs. 
Coronary flow velocity and hemodynamics were monitored 
continuously throughout the protocol. A thromboxane A, 
receptor antagonist, SQ29,548 (Squibb Institute for 
Medical Research, Princeton, NJ) (17), was dissolved in 
alcohol (10 mg/ml), diluted to 1 mg/ml in 2 mM sodium 
(Na,) carbon-oxygen (CO,) and administered in a 0.2 
mg/kg intravenous dose (Fig. 1A). If cyclic coronary flow 
variations were not abolished at this dose, additional 0.2 mg/ 
kg bolus doses were administered at 20 min intervals. When 
cyclic flow variations were abolished, SQ29,548 was infused 
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continuously at 0.2 mg/kg per h for the duration of the antagonists was continued for the duration of the study. 
protocol (Fig. 1A). After 30 min of nonfluctuating blood Epinephrine infusion was initiated, as in Groups 1 and 2, 30 
flow, an intravenous infusion of epinephrine was begun at min after elimination of cyclic flow variation with both 
0.764 pg/min and increased at 20 min intervals to 1.53, 3.82, antagonists; once these flow variations were reestablished, 
7.64, 15.28 and 38.2 pg/min until cyclic flow variations they were observed for 30 min. Yohimbine was adminis- 
returned. Once uniform cyclic flow variations were reestab- tered, as in Groups 1 and 2, to abolish epinephrine-induced 
lished at a constant epinephrine infusion rate, they were cyclic coronary flow variations after administration of both 
monitored for 30 min. serotonin and thromboxane A, receptor antagonists. 
A serotonin antagonist, L Y53,857 (Eli Lilly and Co.) (18) 
was dissolved in saline solution and administered (0.1 mg/kg 
intravenously). Additional 0.05 mg/kg dose increments were 
administered if necessary to abolish the epinephrine-induced 
cyclic coronary flow variations. When cyclic flow variations 
were eliminated, LY53,857 was continuously infused (0.05 
mg/kg per h) for the duration of the experiment. The infusion 
rate of epinephrine was increased again to determine if 
epinephrine induced cyclic flow variations in the presence of 
both thromboxane A, and serotonin receptor antagonists 
(Fig. 1A). If cyclic flow variations were successfully restored 
with an increased epinephrine infusion rate, 30 min of cyclic 
flow variations were observed. Yohimbine, an alpha, antag- 
onist (19) was dissolved in warm saline solution (0.5 mglml) 
and administered intravenously in 0.05 mg doses at 2 min 
intervals until cyclic coronary flow variations were again 
abolished. 
Plasma epinephrine concentrations. Whole blood was col- 
lected from the carotid artery catheter in heparinized test 
tubes (green top tubes) and placed on ice. Tubes were 
centrifuged at 1,000 x g for 20 min at 2 to 4°C. Plasma was 
separated and frozen. Plasma samples were analyzed using 
high pressure liquid chromatography by Smith-Kline Biosci- 
ence Laboratories. 
Blood was collected in all dogs at the end of 30 min of 
cyclic coronary artery flow variations (control) (Fig. 1A to 
C). Second and third blood samples were collected from 
Groups 1 and 2 dogs after 30 min of epinephrine-induced 
cyclic coronary flow variations during each of two periods in 
the protocol (Fig. 1A and B). A second blood sample was 
collected in Group 3 dogs after 30 min of epinephrine- 
induced cyclic variations in the presence of the two receptor 
antagonists (Fig. 1C). 
Group 2 dogs. Cyclic coronary artery flow variations 
were initiated and documented for 30 min after constrictor 
placement in six dogs. LY53,857 was administered to abolish 
cyclic flow variations (0.1 mg/kg bolus followed by 0.05 mg/ 
kg per h continuous infusion for the duration of the study, 
Fig. 1B). When cyclic flow variations had been abolished for 
30 min, a continuous epinephrine infusion was begun as 
described for Group 1 dogs. If cyclic flow variations were 
restored, they were documented for 30 min as in Group 1 
dogs, and SQ29,548 (bolus of 0.2 mg/kg and continuous 
infusion, 0.2 mg/kg per h) was administered to eliminate the 
epinephrine-induced cyclic flow variations. If SQ29,548 
eliminated the cyclic flow variations, the rate of epinephrine 
infusion was increased to restore cyclic flow variations after 
the administration of both thromboxane A, and serotonin 
receptor antagonists. In the event that cyclic flow variations 
were restored a second time, they were documented for 30 
min and yohimbine was administered as described in the 
Group I dogs. 
Statistical analysis. All values are expressed as mean 
values t SEM. Comparisons of values obtained at different 
times within each group of dogs and between treatment 
groups was made by a two-way analysis of variance and a 
Duncan’s multiple range test. A p value <0.05 was used to 
define a significant difference. 
Results 
Cyclic coronary artery flow variations occurred in 22 
(88%) of 25 dogs after constrictor placement. The resultant 
mean and phasic flow velocities after constrictor placement 
in the 22 dogs were 69.6 2 4.3% and 52.7 ? 3.1% of control 
values, respectively. 
Group 3 dogs. Cyclic coronary artery flow variations 
began and were documented for 30 min in nine dogs as in 
Groups 1 and 2 (Fig. 1C). Either SQ29,548 (n = 5) or 
LY53,857 (n = 4) was administered to abolish cyclic flow 
variations, but these antagonists alone were ineffective in 
eliminating them (Fig. 1C). After 30 min of cyclic flow 
variations were observed after administration of the maximal 
dose of one antagonist (SQ29,548, 0.5 to 1.0 mglkg, or 
LY53,857, 0.2 mg/kg), the second antagonist was given to 
eliminate these flow variations and an infusion of both 
Effect of either thromboxane A, or serotonin antagonist on 
cyclic coronary artery flow variation restoration with epineph- 
rine. SQ29,548 (thromboxane A, antagonist) eliminated cy- 
clic coronary artery flow variations in the seven Group 1 
dogs at a mean dose of 0.24 -+ 0.04 mg/kg (range 0.2 to 0.5). 
Continuous infusion of SQ29,548 at a rate of 0.2 mg/kg per h 
prevented cyclic flow variations from returning before epi- 
nephrine infusion; no significant hemodynamic changes were 
observed during the infusion. SQ29,548 did not abolish 
cyclic coronary flow variations in five additional dogs after a 
total dose of 0.68 2 0.10 mg/kg, and these dogs were utilized 
in the Group 3 protocol. 
A total dose of 0.11 t 0.008 mg/kg of LY53,857 (serotonin 
antagonist) was necessary to eliminate cyclic coronary flow 
variations in the six Group 2 dogs, and a continuous infusion 
of 0.05 mg/kg per h prevented the flow variations from 
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Table 1. Summary of Results in the Three Study Groups 
HR 
(beatsimin) 
Ao Pressure (mm Hg) 
Systolic Diastolic Mean 
RPP (beatsimin 
x mm Hg) 
PHF (% control) MNF (% control) 
Peak Nadir* Peak Nadir* 
CFV 
Frequency 
(CFVsih) 
Group 1 (n = 7) 
Control 
Stenosis 
Initial CFVs 
Post SQ 
EPI-CFVs (1) 
Post LY t SQ 
EPI-CFVs (2) 
(n = 4) 
Post yohimbine 
Group 2 (n = 6) 
Control 
Stenosis 
Initial CFVs 
Post LY 
EPI-CFVs (1) 
Post LY t SQ 
EPI-CFVs (2) 
(n = 4) 
Post yohimbine 
Group 3 (n = 9) 
Control 
Stenosis 
Initial CFVs 
Post LY t SQ 
(n = 8) 
EPI-CFVs (1) 
(n = 8) 
Post yohimbine 
(n = 6) 
147 + I5 122 * 9 102 + 6 109 ? 7 
144 + 12 119 r 5 100 2 5 106 + 5 
143 2 10 124 r 6 101 ? 6 108 2 6 
134 + 8 125 + 7 100 2 7 109 t 7 
129 + 7 129 ? 8 87 t 5 101 t 5 
126 f 7t 124 t 8 81 + 4t 95 2 5t 
132 f 9 143 + 11t 96 2 9 112 + 9 
137 lr 7 114 r 8 68 t 8t 83 + 8t 
144 2 5 132 r 6 108 * 6 116 + 6 
144 + 7 132 of: 7 106 f 7 114 _t 7 
136 + 6 129 + 6 104 2 7 112 + 7 
128 + 9t 128 2 5 101 * 6 110 + 6 
129 t 7t 126 & 4 79 2 5t 95 t 4t 
123 2 9t 119+4 14 + 5t 89 2 4t 
124 2 9t 153 + 10t 109 + 11 123 + 10 
131 ? 13 134 r 0.8 17 2 4t 96 + 3t 
18,410 * 3,120 100 100 0 
17,165 + 1,600 52 r 5t - 61 + 8t - 0 
11,860 + 1,129 95 t 11 13 t 3t 120 r 12 17 ? 5t 5.3 2 0.3 
16,907 f 1,717 75 t 9t - 8029 - 0 
16,886 2 1,862 137 f 19 12 2 3t 105 + 12 16 + 5t 8.1 + 1.6 
15,865 ? 1,838 90211 - 106213 - 0 
19,118 + 2,335 120 2 20 59 2 14t 162 + 29t 85 + 20 11.3 + 1.9t 
15,630 + 1,399 82 + 12 - 109+ 11 - 0 
19,131 2 1,215 100 100 0 
19,029 t 1,542 52 2 4t - 7241 - 0 
17,607 f 1,354 95 + 18 5 + 1t 134 + 26 6 2 2t 6.4 + 0.6 
16,319 2 1,352 61 + lt - 79211 - 0 
16,222 + 1,153 107 ? 12 17 + 5t 136 + 12 21 t9t 9.0 + 0.8t 
14,605 t 1,295t 87t8 - 105 2 12 - 0 
18,804 t 1,198 115 + 15 55 + 12t 165 2 25t 86 2 20 12.1 5 2.2t 
17,548 ? 1,149 9229 - 9623 - 0 
121 + 11t 135 * I 94 + 7 108 ? 7 11,036 + 1,142 108 + 11 46 + 12t 140 + 12t 63 * 16t 10.6 + 1.3 
127 ? 6t 122 r I 77 ? 8t 92 2 8t 15,567 ? 1,342t 103 + 11 - 126 2 10 - 0 
*Nadir is the lowest flow velocity recorded (average 3 cycles) just before flow restoration and is expressed as a percent of control blood flow velocity. Walue 
is significantly different from value during control. Values are expressed as mean t SEM. Ao = aortic pressure; CFVs = cyclic coronary artery flow variations; 
EPI = epinephrine; HR = heart rate; LY = a serotonin receptor antagonist, LY53,857; MNF and PHF = mean and phasic (or diastolic) coronary artery flow 
velocity, respectively (both PHF and MNF are expressed as a percent of respective control blood flow before placement of the constrictor); Post = after; RPP 
= product of heart rate and aortic systolic pressure; SQ = a thromboxane receptor antagonist, SQ29,548. 
returning in these dogs before the epinephrine infusion. 
Administration of LY53,857 modestly but significantly de- 
creased heart rate, but did not change arterial pressure 
(Table 1). LY53,857 was ineffective in eliminating cyclic 
coronary flow variations at a total dose of 0.18 f 0.03 mg/kg 
in four additional dogs, and these dogs were also utilized in 
the Group 3 protocol. 
Cyclic coronary flow variations were restored in all seven 
Group 1 dogs with epinephrine infused at an average rate 
of 0.25 t 0.15 cLg/kg per min. The cyclic flow variations 
were restored in all six Group 2 dogs with epinephrine 
at an average infusion rate of 0.11 + 0.02 &kg per min, and 
this rate was not significantly different from the rate required 
in Group 1. The infusion rate of epinephrine required to 
reestablish cyclic flow variations caused no significant he- 
modynamic changes in Group 1, but decreased diastolic 
and mean arterial pressures significantly in Group 2 (Ta- 
ble 1). 
The frequency of cyclic coronary flow variations restored 
by epinephrine did not differ significantly from the initial 
frequency in Group 1 (8.7 2 1.6 cycles/h [epinephrine] versus 
5.3 + 0.3 cycles/h [control], Table 1). However, cyclic 
coronary flow variations were more frequent when restored 
with epinephrine in Group 2 dogs (9.0 -t 0.8 cycles/h [epi- 
nephrine] versus 6.4 +- 0.6 cycles/h [control], Table 1). The 
severity of cyclic coronary flow variations induced by epi- 
nephrine infusion, measured by the lowest flow velocity 
recorded before cyclic flow variation restoration, was not 
significantly different from that recorded during the initial 
cyclic flow variation period for both groups of dogs. A 
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hUU,* 
(mm w 
A. Initial CFVs lmln 6. SQ29.546 
Abolished CFVs [0.2mq/kq) 
C. Epinephrine Restored CFVs 
~0.03~g/kg/min,0.6ng/ml) 
D. LY53657 
Abolished EPI- induced 
E. Epinephrine Restored CFVs 
CFVs (0.4 mg/kg) 
(0.3~g/kg/min, 7.1 q/ml) 
Figure 2. Representative recording from a Group 1 dog. Abbrevia- 
tions as in Figure I. 
I 
F Yohimbine 
Abolished EPI- 
Induced CFVs 
(0.07mglkg) 
representative recording from a Group I dog is shown in 
Figure 2. 
Effect of both thromboxane A, and serotonin antagonists 
on epinephrine-restored cyclic coronary artery flow varia- 
tions. When consistent cyclic coronary flow variations were 
restored with an epinephrine infusion for 30 min in Group 1 
and Group 2 dogs. the alternate antagonist was administered 
to eliminate these epinephrine-induced cyclic flow variations 
(LY53,857 in Group 1 and SQ29,548 in Group 2). The dose of 
LY53,857 necessary to eliminate epinephrine-induced cyclic 
flow variations in Group 1 was 0.11 ? 0.01 mgikg (range 0.1 
to 0.15). The dose of SQ29,548 required to eliminate epi- 
nephrine-induced cyclic Aow variations in Group 2 dogs was 
0.27 t 0.05 mg/kg (range 0.2 to 0.5). SQ29,548, LY53.857 
and epinephrine infusions were continued simultaneously in 
both Group I and Group 2 for the duration of the experi- 
ment. An example of this from a Group I dog is shown in 
Figure 2D. 
In Groups I und 2, the epinephrine infusion rate was 
increased after a 30 min period of no cyclic coronary flow 
variations to determine if a higher plasma concentration of 
epinephrine restored cyclic flow variations in the presence of 
both thromboxane A2 and serotonin receptor antagonists. 
Restoration of cyclic flow variations with epinephrine oc- 
curred in six of the seven Group 1 dogs at an average 
infusion rate of 0.83 2 0.3 pgikg per min (range 0.18 to 2.3) 
(Fig. 2E). Cyclic flow variations could not be restored in a 
seventh dog at an infusion rate of 2.6 pg/kg per min. Cyclic 
flow variations were restored in four of the six Group 2 dogs 
at an average infusion rate of 0.68 + 0.35 Fg/kg per min. 
Epinephrine was ineffective in restoring cyclic flow varia- 
tions in two of six Group 2 dogs at infusion rates of 1.53 and 
2.2 pg/kg per min. The upper limit of epinephrine infusion 
rates was determined by the occurrence of significant hemo- 
dynamic changes. The epinephrine infusion rate required to 
restore cyclic coronary flow variations in the presence of 
both thromboxane AI and serotonin antagonists resulted in 
significant elevation of systolic arterial pressure in Groups 1 
and 2, but restored diastolic and mean arterial pressures to 
control values in these dogs (Table 1, Fig. 2E). 
Group 3 consisted of nine dogs in which LY53,857 (n = 4) 
or SQ29,548 (n = 5) was ineffective in eliminating the initial 
cyclic coronary flow variations. Administration of the sec- 
ond antagonist eliminated cyclic artery flow variations in all 
nine dogs (total dose of LY53,857 0.14 + 0.02 mg/kg, range 
0.05 to 0.25. Group I; total dose of SQ29,548 0.47 2 0.1 mgi 
kg. range = 0.2 to 1.0, Group 2). Continuous infusion of 
both antagonists (LY53.857 0.05 mg/kg per h, Group 1; 
SQ29.548 0.2 mgikg per h, Group 2) prevented cyclic flow 
variations from returning before epinephrine infusion. 
Epinephrine WNS infiirsed in Group 3 only after both 
thromboxane A, and serotonin antagonists were adminis- 
tered. Cyclic coronary flow variations were restored in eight 
of the nine dogs at an average infusion rate of 0.27 2 0.09 pg/ 
kg per min (range 0.06 to 0.70). Cyclic flow variations could 
not be restored with epinephrine in one dog at an infusion 
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rate of 1.17 E.Lg/kg per min. Administration of epinephrine in 
Group 3 did not result in significant hemodynamic changes 
compared with those observed after abolition of cyclic flow 
variations with the two receptor antagonists (Table 1). 
The frequency of cyclic coronary fIow variations in dogs 
with epinephrine-restored cyclic jlow variations was not 
significantly different from the control frequency in any of 
the three groups of dogs (8.1 ? 2.9 versus 6.4 2 0.6 cycles/ 
h, Group 1; 9.7 -t 2.3 versus 5.3 f 0.3 cycles/h, Group 2; 9.4 
t 1.7 versus 6.6 + 0.66 cycles/h, Group 3). 
The lowest mean Jiow velocity (jlow nadir) during epi- 
nephrine-restored cyclic coronary flow variations was signif- 
icantly higher in the presence of the two receptor antagonists 
in all three groups of dogs (Table 1, Fig. 3). In the presence 
of epinephrine and both receptor antagonists, mean and 
phasic coronary blood flow velocity at the nadir of each 
cycle increased to at least the flow velocity after constrictor 
placement (Group 3) and approached control flow before 
constrictor placement in Groups 1 and 2. Maximal mean 
coronary artery flow velocity of each cyclic coronary flow 
during epinephrine infusion also was significantly elevated 
over control flow velocity in all three groups of dogs. Mean 
flow velocities in each of the three groups of dogs are 
summarized in Figure 3. 
Effect of an alpha, antagonist on epinephrine-restored 
cyclic coronary artery flow variations in the presence of 
serotonin and thromboxane A2 receptor antagonists. An 
alpha, antagonist, yohimbine, was administered to eliminate 
epinephrine-restored cyclic coronary flow variations in 17 of 
the 18 dogs in which cyclic flow variations recurred in the 
presence of both LY53,857 and SQ29,548 (Groups 1,2 and 3 
combined). Yohimbine was effective in eliminating these 
epinephrine-induced cyclic flow variations at relatively low 
doses in 16 of the 17 dogs (0.10 2 0.02 mg/kg, n = 6, Group 
1; 0.06 ? 0.02 mg/kg, n = 4, Group 2; 0.06 +- 0.01 mg/kg, n 
= 6, Group 3). This dose resulted in a significant decrease in 
diastolic and mean arterial pressures (Table 1, Fig. 2F). In 
one Group 3 dog, a dose of 0.55 mg/kg yohimbine did not 
eliminate the epinephrine-induced cyclic coronary flow vari- 
ations, and because of hemodynamic depression, no addi- 
tional yohimbine was administered. 
Plasma epinephrine concentration. Plasma epinephrine 
concentration was determined at the end of the initial period 
of cyclic coronary artery flow variations (control), after 30 
min of epinephrine-induced cyclic flow variations in the 
presence of one antagonist (Groups 1 and 2 dogs), and again 
after 30 min of epinephrine-induced cyclic flow variations in 
the presence of the two receptor antagonists (Groups 1, 2 
and 3; Fig. 1A to C). In the event cyclic coronary flow 
variations were not restored, plasma epinephrine levels were 
determined after 30 min of epinephrine infusion at the 
highest infusion rate attempted in the study. Values obtained 
from each group of dogs are shown in Table 2. Cyclic 
coronary flow variations were restored at a plasma epineph- 
A. GROUP I (n=7) 
200 T 
t 
460 - 
% 
Control stsn- High Low ttqh Low Mgh Low 
0516 
w EPI R&&n EPI%&tion 
Control CFVs After SO After LY+SQ 
200 
c 
B. GROUPII In=61 
% 
of 
Control 
Control stsn- Hugh Low 
051s 
- 
H(ph H!ghLq* 
Control CFVs 
EPI Restorotm EPI Restoratm 
After LY After SQ+LY 
t 
C. GROUP III h=9) 
200 
160 
% 
of 
Control 
Control S&M&- HiOh LOW HlQh Low 
- EPI 2tson 
Control CFVs After 8 P+LY 
Figure 3. Coronary artery mean blood flow velocities (CFVs) during 
study protocols (*p < 0.05, different from control). Abbreviations as 
in Figure 1. 
rine concentration 80 (Group 2) to 180 (Group 1) times 
greater than control values in. dogs that received either 
LY53,857 or SQ29,548, respectively, to abolish cyclic flow 
variations. The latter were restored a second time with 
higher plasma concentrations of epinephrine in Groups 1 and 
2. Group 1 required an average of 936 times the plasma 
concentration of epinephrine at control to restore cyclic flow 
variations in the presence of both serotonin and thrombox- 
ane A, antagonists. Group 2 animals required an average of 
604 times the plasma concentration of epinephrine at control 
to restore cyclic flow variations in the presence of the two 
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Table 2. Plasma Epinephrine Concentrations* in the Three Study Groups 
Group I Group 2 Group 3 
Mean 
(Groups 1, 2, 3) 
Control (n) 0.014 * 0.002 (7) 0.047 r 0.014 (6) 0.030 + 0.003 (9) 0.030 + 0.007 (22) 
EPI restored CFVs (n) 2.54 I 0.81 (7) 3.77 ? 1.00 (6)t - 3.11 r 0.63 (13) 
one antagonist 
EPI restored CFVs (n) 13.11 -c 4.84 (6)t 28.4 2 20.1 (4)t 7.21 r 2.02 (8)tS 13.9 + 4.78 (18) 
two antagonists 
EPI infusion; 78.2 k 0 (1) 83.7 + 15.7 (2) 13.7 + 0 (1) 64.8 r 18.3 (4) 
no CFVs (n) 
two antagonists 
*&ml; tsignificantly diierent from control values (p < 0.05); Ssignificantly different from Groups I and 2 when Welch’s approximation for unequal variances 
is used (p = 0.026); abbreviations as in Table 1. 
receptor antagonists. Group 3 dogs, which received epineph- 
rine only after both antagonists were given, required signif- 
icantly less epinephrine to restore cyclic flow variations; that 
is, 240 times that present in the systemic circulation at 
control. Cyclic flow variations could not be restored in four 
dogs with rapid infusion rates of epinephrine; in these dogs, 
plasma epinephrine concentration averaged 21,604 times 
that measured under control conditions. 
Plasma epinephrine values (&ml) were grouped accord- 
ing to the number of antagonists received before restoration 
of cyclic coronary flow variations with epinephrine (Fig. 4). 
Relative protection from cyclic flow variations afforded by 
administration of the two receptor antagonists is suggested 
by the observation that at least 4.5 times the systemic 
concentration of epinephrine was required to restore cyclic 
Figure 4. Plasma epinephrine concentrations grouped according to 
the number of receptor antagonists administered (*p < 0.05, dif- 
ferent from control). Abbreviations as in Figure I. 
68 1 
60 - 
flow variations as compared with the plasma epinephrine 
concentration required after a single receptor antagonist. 
Discussion 
Cyclic coronary artery flow variations. Preliminary re- 
sults reported from our laboratory (12) showed that epineph- 
rine restored cyclic coronary artery flow variations after 
they had been abolished with cyclooxygenase or thrombox- 
ane synthetase inhibitors, as well as with serotonin receptor 
antagonists. Furthermore, preliminary studies (20,21) 
showed that epinephrine reversed inhibition of cyclic flow 
variations after serotonin or thromboxane A, receptor an- 
tagonists were given, alone or in combination. Other inves- 
tigators (11) have shown that bolus or short-duration infu- 
sions of epinephrine restore cyclic coronary flow variations 
after aspirin administration in this animal model, an effect 
attributed to inhibition of adenylate cyclase or increased 
platelet membrane permeability to calcium (22). We recently 
demonstrated (14) that cyclic coronary flow variations are 
abolished in approximately 80% of dogs receiving either 
serotonin or thromboxane A, receptor antagonists, but when 
both antagonists were used simultaneously, cyclic flow 
variations could be eliminated in virtually every dog. From 
these data, we inferred that serotonin and thromboxane 
interact in the process of activating platelets, leading to their 
deposition at sites of endothelial injury and coronary artery 
stenosis and resulting in cyclic coronary flow variations in 
this experimental model. An enhanced antiplatelet effect of 
combined serotonin and thromboxane A, receptor antago- 
nists in vitro was recently reported (23). 
Thromboxane A, and serotonin receptor antagonists. The 
pharmacologic characteristics of the thromboxane A2 and 
serotonin receptor antagonists used in this study have been 
thoroughly documented. SQ29,548 is a selective and potent 
thromboxane A, receptor antagonist that does not alter 
cyclooxygenase, thromboxane synthetase or adenylate cy- 
clase activities, and does not exert thromboxane A, agonist 
properties (17,24). SQ29,548 effectively abolished cyclic 
coronary artery flow variations in 77% of dogs, significantly 
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reduced platelet accumulation at the site of coronary artery 
stenosis and endothelial injury (25,26), and was more than 
300,000 times more effective in inhibiting canine platelet 
aggregation to the thromboxane AZ analogue, U46619, than 
to serotonin (14). 
LY53J.57 is an antagonist at serotonergic receptor sites 
with high ajinity and selectivity (18,27). Unlike the serotonin 
antagonist, ketanserin, it does not lower blood pressure at 
concentrations necessary to block serotonergic receptors 
(18), and it is 300,000 times more selective at vascular 
serotonergic receptor sites than at vascular alpha, sites. 
LY53,857 also does not appear to exert antagonist effects at 
beta,-adrenergic, beta,-adrenergic, histamine (H,), musca- 
rinic or angiotensin receptors in smooth muscle. It does, 
however, have a weak afhnity for alpha,-adrenergic recep- 
tors, but at concentrations 6,000 times greater than required 
to antagonize 5HT, receptors (27). 
Epinephrine restoration of cyclic coronary flow alterations. 
In the present study, we were successful in preventing cyclic 
coronary artery flow variations in approximately 60% of the 
dogs with either a serotonin or a thromboxane A, receptor 
antagonist. Epinephrine restored cyclic flow variations at 
circulating plasma epinephrine concentrations that were sig- 
nificantly higher than control values when administered dur- 
ing a steady state infusion after a single effective receptor 
antagonist. The epinephrine-restored cyclic coronary flow 
variations were effectively eliminated by the addition of the 
second antagonist. The rate of epinephrine infusion was 
increased to restore cyclic flow variations in the presence of 
these two antagonists and the epinephrine concentration 
necessary to overcome the protective effect of the two 
antagonists was determined. Epinephrine was effective in 
restoring cyclic coronary flow variations after administration 
of both thromboxane A, and serotonin receptor antagonists in 
most cases, but greatly elevated circulating plasma epineph- 
rine concentrations were required. There were four dogs in 
which cyclic coronary flow variations could not be restored in 
the presence of both thromboxane A, and serotonin antago- 
nists, even with extremely high circulating epinephrine levels. 
Dogs requiring the administration of both SQ29,548 and 
LY53,857 to abolish the initial cyclic coronary flow varia- 
tions required significantly less circulating epinephrine to 
restore cyclic flow variations (Group 3) than did dogs with 
cyclic flow variations that were restored with epinephrine 
before administration of a second antagonist (Groups 1 and 
2). The combined concentrations of antagonists infused at 
the time of cyclic flow variation restoration with epinephrine 
were considerably less in Group 3, because the period of 
time required for infusion of one antagonist alone was 
greatly reduced (approximately 1 to 1.5 h). This decreased 
infusion time may be partially responsible for the reduced 
epinephrine concentration required to restore cyclic flow 
variations in this group of dogs. 
The involvement of the alpha,-adrenergic receptors in 
epinephrine-restored cyclic coronary fiow variations was 
demonstrated in this study because yohimbine, an alph%- 
adrenergic antagonist (19), effectively eliminated epinephrine- 
induced cyclic flow variations in 94% of the dogs when 
administered at very low concentrations in the presence of 
both thromboxane A, and serotonin receptor antagonists. 
Other studies reported by us (3,16) and by others (28) have not 
demonstrated a primary role for alpha,-receptors in causing 
cyclic coronary flow variations in this experimental model, 
even in the presence of moderately elevated plasma levels of 
epinephrine. However, numerous studies have described the 
synergistic relation between epinephrine and adenosine di- 
phosphate-induced platelet aggregation in vitro, and have 
successfully inhibited this enhanced platelet response by 
yohimbine, clearly implicating alpha, receptors in this re- 
sponse (29-33). Increased cytoplasmic calcium concentration 
and platelet aggregation were observed when pairs of agonists 
were added to human platelets within 20 s of each other, 
including epinephrine and the thromboxane A, analogue, 
U46619, and epinephrine and thrombin. An increase in cal- 
cium in response to a single agonist appears to lower the 
aggregation threshold for subsequent agonists (9). Alpha,- 
receptor blockade may have been particularly effective in 
these experiments because potentially important synergistic 
agonist effects on platelet aggregation (serotonin and throm- 
boxane A,) were pharmacologically blocked, leaving rela- 
tively weaker aggregation effects due to alpha,-receptor acti- 
vation. Yohimbine likely eliminated epinephrine-induced 
cyclic coronary flow variations by antagonizing the alpha,- 
receptor on platelets that had been stimulated with epineph- 
rine. 
Plasma epinephrine concentrations have been measured 
in humans during a variety of physiologic and pathologic 
situations. Benedict and Grahame-Smith (34) measured cir- 
culating epinephrine concentrations in patients with myocar- 
dial infarction, with and without cardiogenic shock. Patients 
admitted with cardiogenic shock did not have markedly 
different plasma epinephrine concentrations (1.13 + 0.19 ng/ 
ml) from those of patients admitted with uncomplicated 
myocardial infarction (0.57 ? 0.21 ng/ml). Escourrou et al. 
(35) measured plasma epinephrine concentrations in humans 
exercising under normoxic and hypoxic (11 to 12% 0,) 
conditions. Plasma epinephrine level at rest in seven humans 
(normoxic) was 0.32 ? 0.06 ng/ml. Significant elevations in 
epinephrine concentration were observed when subjects 
were exercised at 75% V02max in both normoxic (0.46 + 0.06 
&ml) and hypoxic (0.92 ? 0.17 rig/ml) conditions. 
The results from the present study suggest that the plasma 
levels of epinephrine required to restore cyclic coronary 
artery flow variations in the presence of both thromboxane A, 
and serotonin receptor antagonists are greatly in excess of 
values usually encountered in patients with myocardial infarc- 
tion and in individuals who are exercising under normal or 
hypoxic conditions. The presence of these two antagonists 
appears, at least in our experimental model, to provide 
substantial protection against epinephrine-induced cyclic cor- 
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onary artery flow variations. Even the concentration of epi- 
nephrine required to restore cyclic flow variations in the 
presence of one receptor antagonist was at the upper limit or 
slightly higher than systemic epinephrine concentrations usu- 
ally encountered physiologically or clinically. 
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